Hisaji Oshima

Hisaji Oshima


Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
KIKeisuke Izumi
Keisuke Izumi
OMOkinori Murata
Okinori Murata
MHMisako Higashida-Konishi
Misako Higashida-Konishi
YKYuko Kaneko
Yuko Kaneko
HOHisaji Oshima
Hisaji Oshima
TTTsutomu Takeuchi
Tsutomu Takeuchi
Polymyalgia rheumatica (PMR) is an inflammatory disorder characterized by pain and stiffness in the shoulders, hips, and proximal limbs; it usually affects elderly patients. The effectiveness of methotrexate and tocilizumab in PMR treatment has not been extensively studied. Thus, we aimed to assess the steroid-sparing effect of tocilizumab and methotrexate in PMR in clinical practice. Consecutive patients with PMR in our hospitals, who were included in our retrospective cohort, were reviewed between 2005 and 2015 and divided into the following groups according to their treatments: prednisolone or none (prednisolone group), methotrexate ± prednisolone (methotrexate group), or tocilizumab ± prednisolone (tocilizumab group). The prednisolone dose at the last follow-up was compared. A total of 227 patients with an average age of 74 years were enrolled. No difference in baseline characteristics was found among the three groups. The prednisolone dose at the last follow-up was lower (0 vs. 3.0 vs. 3.5 mg/day, p < 0.001) and the prednisolone discontinuation rate was higher (80.0% vs. 28.3% vs. 18.8%, p < 0.0001) in the tocilizumab group than in the prednisolone and methotrexate groups. This study suggested that tocilizumab has a steroid-sparing effect in PMR. Tocilizumab can be an option in the management of PMR. Future studies are warranted to confirm our findings.

1 October 1991 in Clinical Chemistry
Verified
Journal Article
Open access
PDF file
Hiroaki TanakaHiroaki Tanaka
Hiroaki Tanaka
HAH Akama
H Akama
YIY Ichikawa
Y Ichikawa
MHM Homma
M Homma
HOHisaji Oshima
Hisaji Oshima
We measured glucocorticoid receptors (GR) in mononuclear leukocytes (MNL) isolated from peripheral blood of 145 apparently healthy volunteers (86 men and 59 women). An age-related decrease in the number of GR was suggested between subjects younger than 20 years and elderly subjects; there was no apparent seasonal variation in GR. Gender difference in the number of GR was not significant, although women showed slightly fewer GR. Eight patients with dermatomyositis/polymyositis were examined to determine whether the number of GR in MNL could be down-regulated by their cognate ligands. The number of GR in MNL from these patients was significantly decreased one month after the initiation of prednisolone therapy. However, in normal subjects, the GR in MNL did not demonstrate circadian variation, in contrast to concentrations of plasma cortisol.

19 November 2020 in Journal of Bone and Mineral Metabolism
Verified
Journal Article
Closed access
PDF file
ITIkuko Tanaka
Ikuko Tanaka
YTYoshiya Tanaka
Yoshiya Tanaka
SSSatoshi Soen
Satoshi Soen
HOHisaji Oshima
Hisaji Oshima

24 September 2022 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
MHMisako Higashida-Konishi
Misako Higashida-Konishi
MAMitsuhiro Akiyama
Mitsuhiro Akiyama
TSTatsuya Shimada
Tatsuya Shimada
SHSatoshi Hama
Satoshi Hama
TOTatsuhiro Oshige
Tatsuhiro Oshige
YOYutaka Okano
Yutaka Okano

11 August 2021 in Modern Rheumatology
Verified
Journal Article
Closed access
PDF file
ITIkuko Tanaka
Ikuko Tanaka
YTYoshiya Tanaka
Yoshiya Tanaka
SSSatoshi Soen
Satoshi Soen
HOHisaji Oshima
Hisaji Oshima
A post hoc analysis of the Teriparatide Once-Weekly Efficacy Research for Glucocorticoid-induced Osteoporosis (TOWER-GO) study was performed to examine the effect of once-weekly administration of 56.5 μg teriparatide on primary prevention of glucocorticoid-induced osteoporosis (GIOP). Of the subjects of the TOWER-GO study, 73 were included. The percentage changes from baseline in lumbar spine bone mineral density (BMD) and bone turnover markers were evaluated over 72 weeks with once-weekly teriparatide and once-weekly alendronate. The percentage change of lumbar spine BMD from baseline at 72 weeks was significantly increased in both groups. Bone formation markers were significantly increased by teriparatide administration, although they were slightly decreased by alendronate administration. Bone resorption markers were gradually decreased by teriparatide, whereas alendronate markedly decreased them within 4 weeks. No major safety concerns arose. In this primary prevention study of GIOP, comparable increases in BMD were observed between alendronate and once-weekly teriparatide. More desirable changes in bone markers were observed with teriparatide administration. These data suggest that once-weekly teriparatide is effective in primary prevention of GIOP.

Verified
Journal Article
Open access
PDF file
MHMisako Higashida-Konishi
Misako Higashida-Konishi
KIKeisuke Izumi
Keisuke Izumi
SHSatoshi Hama
Satoshi Hama
HTHiroshi Takei
Hiroshi Takei
HOHisaji Oshima
Hisaji Oshima
YOYutaka Okano
Yutaka Okano
In seronegative arthritis with extremity edema, it is difficult to differentiate between remitting seronegative symmetrical synovitis with pitting edema syndrome (RS3PE) and seronegative rheumatoid arthritis (SNRA). We compared the clinical characteristics of RS3PE and SNRA in patients with and without malignancies. We retrospectively examined patients diagnosed with RS3PE (McCarty criteria) and SNRA at our hospital in 2007–2020. Malignancy was diagnosed within 2 years before or after RS3PE or SNRA diagnosis. Overall, 24 RS3PE and 124 SNRA patients were enrolled. The median ages were 79.5 and 68.5 years, and men comprised 54.2% and 37.1% of RS3PE and SNRA patients, respectively. RS3PE patients had higher inflammation levels (p = 0.004) and more incidences of malignancy (p = 0.034). Matching for age and sex, RS3PE patients had higher inflammation levels (p = 0.021) and more incidences of malignancy (p = 0.005). Overall, odds ratios (ORs) for malignancy were higher for older age (OR 1.06, p = 0.037), male sex (OR 4.34, p = 0.007), RS3PE patients (OR 4.83, p = 0.034), and patients with extremity edema (OR 4.83, p = 0.034). Inflammation levels and associated factors of malignancy were higher in RS3PE patients than in SNRA patients. Patients who are older, male, with extremity edema, or had RS3PE should be screened for malignancies.